Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Abraxas and RAP80 Form a BRCA1 Protein Complex Required for the DNA Damage Response

Bin Wang, Shuhei Matsuoka, Bryan A. Ballif et al. · Science · 2007 · 691 citations

Life Sciences, Molecular Biology, Oncology +17

Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer

Manuel Cobo, Dolores Isla, Bartomeu Massutí et al. · Journal of Clinical Oncology · 2007 · 442 citations · Full text

Medicine, Molecular Medicine, Oncology +10

BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.

Jennifer E. Quinn, Richard D. Kennedy, Paul B. Mullan et al. · PubMed · 2003 · 402 citations

Medicine, Molecular Biology, Oncology +17

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer

Sven Rottenberg, Anders O.H. Nygren, Marina Pajic et al. · Proceedings of the National Academy of Sciences · 2007 · 304 citations · Full text

Medicine, Cancer Biology, Oncology +16